Analysts await Bovie Medical Corporation (NASDAQ:BVX) to report earnings on Mar, 17 for the fiscal quarter ending Dec 2015.

They expect $-0.06 EPS, up 100% or $0.06 from last year’s $-0.12 per share.

At the moment 2 analysts are watching Bovie Medical Corporation (NASDAQ:BVX), 0 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 7.40 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 9.20 million whilst for the year ending Dec-16, 2 analysts have a mean target of 36.79 million.

In terms of earnings per share, 1 analyst has a -0.05 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.05 EPS mean target and for the quarter ending Jun-16 there are 2 estimates of -0.15 EPS.

The biggest institutional shareholders in Bovie Medical Corporation include Great Point Partners Llc which owns 3 million shares in the company valued at $5.90 million. RENN Universal Growth Investment Trust PLC is the second biggest holder with 3 million shares currently valued at 7.75 million whilst Renn Capital Group Inc has 700 K million shares valued at 1.47 million.

Total shares held by institutions as of the most recent company filings are 1,836,721 with a reported 209,250 bought and 48,808 sold. These holdings make up 6.75% of the company’s outstanding shares.

Currently insiders hold 1,786,282 shares in the business which makes up 6.57% of shares. The biggest holder currently is Mr. Andrew Makrides who owns 611,972 shares (2.25% of those outstanding), whilst Mr. Moshe Citronowicz holds 426,504 (1.57% of shares outstanding) and Mr. J. Robert Saron holds 393,698 (1.45% of shares outstanding).

The stock decreased 2.70% or $0.05 during the last trading session, hitting $4.00. Bovie Medical Corporation (NASDAQ:BVX) has risen 42.5% over the past 6 months and is uptrending.